UNSPSC 51124500: Antiarrythmic sulfur compounds

This classification denotes made from or based in part on inorganic or organic compounds that contain sulfur as an integral part of their molecule, substances called sulfur compounds, that prevent or treat irregular heartbeat, disturbances of normal rhythmic heart beating, or normal operation of myocardial contraction, thus the term ANTIARRYTHMIC SULFUR COMPOUNDS.

UNSPSC 51124500 Antiarrhythmic sulfur compounds, a Class code, covers emergency and critical-care medications supplied to fire rescue services, hospital systems, and state health agencies — specifically cardiac and hemodynamic agents used in advanced life support protocols. State and local health authorities procure these medications as sealed-bid or cooperative-purchasing contracts for paramedic and emergency medical services use, with strict expiration-date and shelf-life requirements, OSHA hazard communication documentation, and cold-chain or climate-controlled delivery. Issuing bodies include municipal fire departments (Tampa Fire Rescue), state pharmacy benefit programs (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administering contracts across dozens of jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participating states).

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications—370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials—with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent small local business enterprise bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intent to establish direct-to-manufacturer contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products, requiring vendors to distribute through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026 and a two-year initial term. All three solicitations require cGMP and DSCSA compliance and impose strict product-availability and expiration-date warranties.